BAY 43-9006 is a kinase inhibitor that induces apoptosis in a variety of tumor cells. Here we report that treatment with BAY 43-9006 results in marked cytochrome c and AIF release into the cytosol, caspase-9, -8, -7, and -3 activation, and apoptosis in human leukemia cells (U937, Jurkat, and K562). Pronounced apoptosis was also observed in blasts from patients with acute myeloid leukemia. The Ras/Raf/mitogen-activated protein kinase (MEK) 2 /extracellularsignal-regulated kinase (ERK) cascade plays a critical role in relaying signals from cell surface receptors to various cytoplasmic and nuclear proteins involved in diverse biological process such as cell growth, transformation, differentiation, and apoptosis (1). Aberrant activation of this pathway has been implicated in the development of many tumor types, and constitutive activation of this pathway has been observed in ϳ30% of all human cancer. The serine/threonine Raf kinase family, which consists of three proteins, C-Raf (also referred to as Raf-1), B-Raf, and A-Raf, is an essential component of this pathway (1, 2). Strikingly, B-Raf-activating mutations have been observed in ϳ70% of malignant melanomas (3, 4) and at lower frequencies in a number of other human cancer types, including colorectal (3, 5), ovarian, and papillary thyroid carcinomas (3, 6, 7). Moreover, overexpression of constitutively active c-Raf is sufficient to induce transformation of NIH 3T3 cells (8). Increased Raf/MEK/ERK activity has also been observed in a variety of leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (9, 10). In addition, constitutive activation of this pathway diminishes apoptosis in hematopoietic cells (11) and abrogates the cytokine dependence of several human and murine cytokine-dependent hematopoietic cells lines (e.g. TF-1, FDC-P1, and FL5.12) (12). Conversely, inhibition of this pathway by pharmacologic MEK inhibitors such as PD98059 or U0126 enhances apoptosis induction by a variety of agents, including paclitaxel (13) UCN01 (14), STI571 (15), proteasome inhibitors (16), and lovastatin (17). For these reasons, disrupting the Ras/Raf/MEK/ERK pathway represents an attractive anticancer strategy, particularly in leukemia cells.
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BAY 43-9006, a novel bi-aryl urea, has shown promising preclinical activity against a variety of tumor cell types and is currently undergoing phase II/III clinical evaluation (18 -20) . Although it was initially developed as a specific inhibitor of C-Raf and B-Raf, subsequent studies revealed that this compound also inhibits several other important tyrosine kinases involved in tumor progression, including vascular epidermal growth factor receptor-2, vascular epidermal growth factor receptor-3, platelet-derived growth factor receptor-␤, Flt3, and c-Kit (21) . Interestingly, BAY 43-9006 has been shown to inhibit C-Raf and wild type as well as mutant V600E B-Raf kinase activities in vitro and to diminish MEK/ERK activation in various tumor cell lines, including those harboring mutant Ras or B-Raf (21) (22) (23) .
Several studies have shown that myeloid cell leukemia-1 (Mcl-1), a Bcl-2 family member, plays a pivotal role in cell survival, particularly in hematopoietic cells. For example, depletion of Mcl-1 using antisense oligonucleotides rapidly triggers apoptosis in U937 cells (24) . Moreover, inducible deletion of Mcl-1 in mice resulted in loss of early bone marrow progenitor populations, including hematopoietic stem cells (25) . Deletion of Mcl-1 during early lymphocyte differentiation also increased apoptosis and arrested development at the pro-B-cell and double-negative T-cell stages. In addition, specific ablation of Mcl-1 in peripheral B-and T-cell populations resulted also in their rapid loss (26) . On the other hand, selective overexpression of Mcl-1 in hematopoietic tissues of transgenic mice promotes the survival of hematopoietic cells and enhances the outgrowth of myeloid cell lines (27) . Finally, overexpression of Mcl-1 protects cells from apoptosis induced by a variety of agents, including UV, tumor necrosis factor-related apoptosis-inducing ligand, etoposide, staurosporine, actinomycin D, among others (28 -31) . Such evidence suggests that Mcl-1 may play a critical role in the survival of leukemia and possibly other malignant hematopoietic cells. Interestingly, expression of Mcl-1 has been shown to be dependent upon an intact MEK/ERK pathway in both hematopoietic (32) and nonhematopoietic cells (33) .
Currently, the one or more mechanisms by which BAY 43-9006 induces cell death in human leukemia cells remain to be fully elucidated. Here we report that BAY 43-9006 potently induces mitochondrial injury and apoptosis in these cells in association with a pronounced and MEK/ERK-independent reduction in Mcl-1 expression. Moreover, prevention of BAY 43-9006-mediated Mcl-1 down-regulation by ectopic expression of an Mcl-1 construct substantially diminishes BAY 43-9006-induced mitochondrial injury and apoptosis. Finally, the present results indicate that BAY 43-9006 down-regulates Mcl-1 expression through inhibition of translation, rather than through a transcriptional, post-translational, or caspase-dependent mechanism.
MATERIALS AND METHODS
Cells-The human leukemia U937, Jurkat, and K562 cells were cultured as previously reported (34) . U937 cells stably overexpressing Mcl-1 were kindly provided by Dr. Ruth Craig (Dartmouth Medical School, Hanover). These cells were obtained by transfecting U937 cells with a pCEP4-Mcl-1construct that encodes for the 40-kDa Mcl-1 protein. Stable single cell clones were selected in the presence of 400 g/ml hygromycin. Thereafter, cells from each clone were analyzed for Mcl-1 expression by Western blot. A Tet-On Jurkat cell line inducibly expressing constitutively active MEK1 under doxycycline control was previously described (34) .
Isolation of Patient-derived Leukemic Blasts-Leukemic blasts were obtained with informed consent from the peripheral blood of several patients with acute myeloblastic leukemia (AML), FAB subtype M2. These studies have been sanctioned by the Investigational Review Board of Virginia Commonwealth University/Medical College of Virginia, and all patients provided informed consent. In each case, the percentage of blasts in the peripheral blood was Ͼ70%. Blood was collected into heparinized syringes, diluted 1:3 with RMPI 1640 medium, and transferred as an overlayer to centrifuge tubes containing 10 ml of Ficoll-Hypaque (specific gravity, 1.077-1.081). After centrifugation at room temperature for 30 min, the interface layer, containing predominantly leukemic blasts, was extracted with a sterile Pasteur pipette, suspended in RPMI medium, and washed three times. Leukemic blasts, which displayed Ͼ90% viability by trypan blue exclusion, were then diluted into RPMI medium containing 10% fetal calf serum at a concentration of 10 6 cells/ ml, and exposed to drugs as described in the case of continuously cultured cell lines.
Reagents-BAY 43-9006 (Bayer, West Haven, CT) was provided by Dr. John Wright, Cancer Treatment and Evaluation Program, NCI, National Institutes of Health (Bethesda, MD). It was dissolved in Me 2 SO, and aliquots were maintained at Ϫ80°C. MG132 was purchased from Calbiochem; cycloheximide and actinomycin D were purchased from Sigma. SB202190 was purchased from Alexis Corp. (San Diego, CA). Rapamycin and U0126 were purchased from Cell Signaling Technology (Beverly, MA). The broad spectrum cell-permeable caspase inhibitor, z-VAD-FMK was purchased from Enzyme Systems Products (Livermore, CA). All reagents were prepared and used as recommended by their suppliers.
Assessment of Apoptosis-Apoptotic cells were routinely identified by Annexin V-fluorescein isothiocyanate staining as previously described (35) . Briefly, 10 5 cells were collected, washed in cold phosphate-buffered saline, and then resuspended in binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) containing fluorescein-labeled annexin V (BD Pharmingen) and propidium iodide. Samples were incubated for 15 min and then analyzed by flow cytometer (BD Biosciences FACScan).
Quantitative Real-time PCR-U937 cells were left untreated or treated with 10 M BAY 43-9006 for the indicated period after which they were lysed and total RNA was extracted using the RNeasy mini kit (Qiagen). Quantitative real-time PCR analysis was carried out on the ABI Prism 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) using the TaqMan One Step PCR Master Mix Reagents Kit (polynucleotide: 4309169) as recommended by the manufacturer. The cycling conditions were: 48°C/30 min; 95°C/10 min; and 40 cycles of 95°C/15 s and 60°C/1 min. The cycle threshold was determined to provide the optimal standard curve values (0.98 -1.0). The probes (5Ј-TCAAGTGTTTAGCCACAAAGGCACCAAAAG-3Ј) and Mcl-1-specific primers (forward, GGGCAGGATTGTGACTCTCATT; reverse, 5Ј-GATGCAGCTTTCTTGGTTTATGG-3Ј) were designed using the Primer Express 2.0 version. The probes were labeled at the 5Ј-end with 6-carboxyfluoresceine and at the 3Ј-end with 6-carboxytetramethylrhodamine. Ribosomal RNA (18 S rRNA) was used as endogenous control. Each sample was tested in triplicate, and the Mcl-1 mRNA level was normalized to that of 18 S rRNA.
Transient Transfection and Reporter Gene Assay-K562 cells were transiently transfected using Amaxa nucleofector TM (Koeln, Germany) as previously described (36) . Constitutively active MNK1 T332D and eIF4E (wild type) were kindly provided by Dr. J. A. Cooper (Fred Hutchinson Cancer Research Center, Seattle, WA) (37). PcDNA3.1-Mcl-1 was a generous gift from Dr. R. W. Craig. Empty vector pcDNA3.1 was purchased from Invitrogen. Reporter gene assays were carried out as previously described (38) . Briefly, cells were cotransfected with a Ϫ203/ ϩ10-Mcl-1-pGL2 plasmid (39) in which firefly luciferase is driven by the Ϫ203 to ϩ10 element of the Mcl-1 gene promoter, or the pGL2-basic empty vector (Promega, Madison, WI) and pRL-TK-luc plasmid encoding for Renilla luciferase. Cells were incubated for 6 h and then treated with BAY 43-9006 for an additional 20 h, after which the activity of firefly and Renilla luciferases was measured using the Dual-Luciferase reporter assay system (Promega). Values for firefly luciferase activity were normalized to those obtained for Renilla luciferase activity.
Immunoprecipitation and Immunoblotting-For immunoprecipitation, cells were lysed in buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, antiproteases (10 g/ml of leupeptin and aprotinin, 1 mM phenylmethylsulfonyl fluoride), and 1% Triton X-100 after which 500 g of protein lysate was subjected to immunoprecipitation using the designated antibodies. Immunoblotting was performed using the immunoprecipitates or the whole cells lysates as previously described in detail (35) . The primary antibodies used in this study were as follows: caspase-3, Bax, caspase-7, Bcl-2, and Mcl-1 (BD Pharmingen); Caspase-8 (Alexis Corp.); poly(ADP-ribose) polymerase (PARP, Biomol Research Laboratories, Plymouth Meeting, PA); Bcl-x L XIAP, total and Phospho-ERK1/2 (Thr-202/Tyr-204), ubiquitin, cleaved caspase-9, cleaved caspase-3, phospho-4EBP1 (Ser-65), phospho-eIF4E (Ser-209), phospho-eIF4G (Ser-1108), phospho-p90RSK (Ser-380), phospho-p70S6K (Thr-389), phospho-p38 (Thr-180/Tyr-182), and phospho-JNK1 (Thr-183/Tyr-185) (Cell Signaling Technology); eIF4G (BD Transduction Laboratories); Bim, HA, cytochrome c, AIF, total and phosphorylated Bcr-abl, eIF4E, p70S6K, myc, JNK1, and p38 (Santa Cruz Biotechnology, Santa Cruz, CA); and Bak and ␣-tubulin (Calbiochem).
Mcl-1 Protein Stability-U937 cells were washed in phosphate-buffered saline and cultured at a density of 5 ϫ 10 6 cells, in methionine-free RPMI for 15 min, then labeled with 100 Ci/ml [ 35 S]methionine (ICN, Biomedicals, Inc., Irvine, CA) for 60 min. Cells were then washed in phosphate-buffered saline and cultured in complete RPMI containing fetal bovine serum and excess of cold methionine (10 mM) and cysteine (5 mM) for the indicated periods in the presence or absence of BAY 43-9006 with or without the proteasome inhibitor MG132. At the end of the indicated intervals, 10 7 cells were collected and subsequently subjected to immunoprecipitation using Mcl-1 antibodies as described above. The immunoprecipitates were subjected to SDS-PAGE followed by autoradiography. m 7 -GTP-Sepharose Chromatography-Following stimulation, cells were lysed in lysis buffer as indicated above. 500 g of protein lysates was incubated with 50 l of m 7 -GTP-Sepharose beads (Amersham Biosciences) for 2 h at 4°C after which the beads were washed three times and boiled in Laemmli buffer for 5 min, and following centrifugation, the supernatants containing the proteins were subjected to Western blot analysis.
Subcellular Fractionation-Leukemic cells (4 ϫ 10 6 ) were lysed using digitonin buffer (35) , after which cytosolic and membrane fractions were separated by centrifugation, solubilized in Laemmli buffer, and boiled for 5 min. Proteins were analyzed by Western blot to evaluate cytochrome c release into the cytosol.
Statistical Analysis-The significance of differences between experimental conditions was determined using the Student's t test for unpaired observations. Virtually identical results were obtained in Jurkat lymphoid leukemia cells (Fig. 1B) . Exposure of U937 cells to 10 M BAY 43-9006 at varying intervals resulted in induction of apoptosis that was detected as early as 4 h after drug treatment. Longer exposure intervals resulted in a marked increase in cell death (e.g. 55 and 70% at 24 and 48 h, respectively). Essentially equivalent findings were observed when Jurkat cells were examined (data not shown). Furthermore, exposure to BAY 43-9006 resulted in a release of cytochrome c and AIF into the cytosol (Fig. 1D ) accompanied by cleavage of caspases-7, -8, -9, and -3 as well as PARP (Fig. 1E ). These events were readily apparent after 8 h of treatment and became more pronounced after 20 h. Together, these findings indicate that BAY 43-9006 results in a striking induction of caspase activation, mitochondrial injury, and apoptosis in human myeloid and lymphoid leukemic cells.
RESULTS

Treatment with BAY 43-9006 Results in a Marked
Exposure of U937 Cells to Is Associated with a Decrease in ERK Phosphorylation-Dose-response studies (Fig. 2) revealed that exposure of U937 cells to BAY 43-9006 at concentration as low as 5 M resulted in a discernable decrease in ERK phosphorylation as early as half an hour after beginning of exposure, and this decrease persisted at 4 and 8 h of drug administration. Exposure to 7.5 and 10 M BAY 43-9006 produced even more pronounced reductions in ERK phosphorylation.
In contrast, total levels of ERK were unchanged. These findings confirm that, as previously described in other cell types (21, 22 (40, 41) , expression of these proteins was monitored in U937 cells following treatment of cells with BAY 43-9006 (10 M) for varying intervals (Fig. 3A) . After 20 h of treatment, a decline in protein levels of Bcl-x L , Bak, Bim, as well as cleavage of Bcl-2, Bax, and XIAP were detected, however, no major changes were observed at earlier intervals. cells were exposed to the designated concentration of BAY 43-9006 for 24 h after which the percentage of apoptotic cells was determined by annexin V analysis as described under "Materials and Methods." C, U937 cells were exposed to 10 M BAY 43-9006 for the designated period after which apoptosis was determined as above. D, U937 cells were treated with BAY 43-9006 for the designated period, after which mitochondria-free cytosolic fractions were obtained as described under "Materials and Methods" and subjected to Western blot analysis to monitor release of cytochrome c and AIF. Alternatively, whole cell lysates were obtained, and subjected to Western blot analysis to monitor expression of procaspase-3, caspase-8, caspase-7, cleaved caspase-9 (c-casp-9), and PARP. The blots were subsequently re-probed with anti-tubulin (Tub) antibodies to document equivalent loading and transfer. The results of a representative study are shown; two additional experiments yielded equivalent results. The finding that these changes were detected after caspase activation argues against the possibility of a primary role for these phenomena in BAY 43-9006-mediated cell death. In addition, no change in Bid protein level was noted. In striking contrast, levels of the anti-apoptotic protein Mcl-1 protein declined rapidly (e.g. over 2 h) following treatment with BAY 43-9006, and by 8 h expression was essentially absent (Fig. 3A) . 5 M, and at 10 M, the large majority of cells was apoptotic (ϳ75%). Time-course studies revealed a time-dependent cleavage of PARP that was first detected at 4 h of treatment and became more apparent at later exposure intervals (8, 16 , and 24 h) (Fig. 4B ). Notably, a rapid decline in ERK phosphorylation and Mcl-1 protein levels were also observed, analogous to results in U937 cells. In contrast, no major changes were noted in Bcr-abl expression or phosphorylation until considerably later intervals (e.g. 24 h) when the large majority of cells were apoptotic (Fig. 4B) . Lastly, attempts were made to determine whether BAY 43-9006 also triggered cell death in primary human leukemia blasts, or whether this phenomenon was restricted to continuously cultured cell lines. Significantly, treatment with BAY 43-9006 resulted in a marked dose-dependent increase in cell death in human leukemia blasts isolated from 2 patients with AML (FAB classification M2; Fig. 4C ). An increase in apoptosis at 24 h was detected at a BAY 43-9006 concentration as low as 2.5 M (35-45%) and further increases in cell death were observed at higher concentrations. For example, at 10 M BAY 43-9006 induced 60 and 80% apoptosis in blasts from patient #1 and patient #2, respectively. Studies involving blasts from two additional patients yielded essentially identical results (data not shown). These events were accompanied by pronounced PARP cleavage (Fig. 4D) . Notably, a marked decrease in Mcl-1 protein levels and in ERK phosphorylation was also observed in both samples, whereas the total ERK1/2 level remained unaffected. Thus, exposure to BAY 43-9006 leads to a marked increase in lethality in primary human AML blasts in association with diminished ERK phosphorylation and Mcl-1 down-regulation, analogous to findings in continuously cultured leukemia cell lines.
Mcl-1 Down-regulation by BAY 43-9006 Is Independent of MEK/ERK, p90RSK, mTOR, and p70S6K
Inactivation-Previous studies have indicated that interruption of the Raf/MEK/ERK pathway by the MEK inhibitor PD98059 decreases basal levels of Mcl-1 (42) and attenuates Mcl-1 protein accumulation in response to various cytokines, including epidermal growth factor, interleukin-5, and stem cell factor (33). Consequently, the possibility that BAY 43-9006 down-regulates Mcl-1 through inhibition of the Raf/MEK/ERK pathway appeared plausible. To test this possibility, Jurkat cells (MT6) inducibly expressing a constitutively active MEK1 under the control of a doxycycline-responsive promoter was employed. Western blot analysis revealed that addition of doxycycline resulted in a substantial increase in expression of constitutively active MEK1 and phospho-ERK1/2 in both control and BAY 43-9006-treated cells (Fig. 5A) . However, exposure to BAY 43-9006 resulted in equivalent decreases in Mcl-1 expression in the absence or the presence of doxycycline. Similar results were obtained in two additional MEK1-inducible clones and in U937 cells stably expressing con- A, K562 cells were exposed to the indicated concentrations of BAY 43-9006 for 24 h after which the extent of apoptosis was determined using annexin V staining. B, K562 cells were treated with 6 M BAY 43-9006 for the designated intervals after which cell lysates were prepared and subjected to Western blot analysis using the indicated antibodies. C, leukemia blasts were isolated as described under "Materials and Methods" from the peripheral blood of two patients with AML (FAB classification M2), exposed to the designated concentration of BAY 43-9006 for 24 h, after which the extent of apoptosis was determined using annexin V analysis. Each sample was performed in duplicate, and the means Ϯ S.D. were calculated. D, alternatively, blasts were lysed after 6 h of treatment and subjected to Western blot analysis to monitor the level of phosphorylated ERK1/2, total ERK1/2, and Mcl-1 proteins. The protein lysates were also prepared after 24 h of exposure to monitor PARP cleavage by Western blot analysis. Total ERK in these experiments also serves as control for loading and transfer of proteins.
stitutively active MEK1 (43) (data not shown). Effects of BAY 43-9006 on p90RSK and p70S6K were also examined. As shown in Fig. 5B , a time-course study revealed that BAY 43-9006 did not have a major effect on p90RSK phosphorylation. Expression and phosphorylation of p70S6K were also unperturbed by treatment with BAY 43-9006. Consistent with these findings, induction of constitutively active MEK1 resulted in increased phosphorylation of p90RSK (Fig. 5C ), whereas BAY 43-9006 continued to down-regulate Mcl-1 (Fig. 5A ). In addition, pretreatment of cells with the MEK inhibitor U0126 (10 M), which clearly decreased ERK and p90RSK phosphorylation, resulted in only a very modest decline in Mcl-1 protein levels (Fig. 5D) . Notably, treatment of cells with the mTOR inhibitor rapamycin (20 nM) also failed to decrease Mcl-1 protein levels despite markedly diminishing phosphorylation of p70S6 kinase (Fig. 5E) . Together, these findings argue against the possibility that BAY 43-9006 down-regulates Mcl-1 through inhibition of Raf/MEK/ERK1/2, p90RSK, mTOR, or p70S6K.
Finally, activation of the stress-activated protein kinases p38 and JNK were examined. Consistent with previous studies (19) , BAY 43-9006 induced a marked decrease in p38 phosphorylation without affecting total protein levels. This was associated with an increase in JNK phosphorylation (Fig. 5F ). However, inhibition of p38 or JNK activation with SB202190 or SP600125, respectively, did not result in major change in Mcl-1 protein levels (data not shown), arguing against the possibility that BAY 43-9006 down-regulates Mcl-1 through a p38-or JNK-dependent mechanism.
Mcl- (Fig. 6B) . After 4 h of treatment, Mcl-1 mRNA returned to near basal levels. In addition, inhibition of transcription using actinomycin D (5 g/ml) resulted in a decrease in Mcl-1 protein levels, and co-treatment with BAY 43-9006 resulted in a further decline (Fig. 6C) , suggesting an alternative, transcription-independent mechanism of Mcl-1 down-regulation by this agent. Collectively, these and the preceding findings are most consistent with the notion that BAY 43-9006 down-regulates Mcl-1 protein at either the translational or at the post-translational level. (Fig.  8B) . In addition, measurement of protein synthesis by [ 35 S]methionine incorporation (Fig. 8C) revealed that BAY 43-9006 inhibited Mcl-1 protein synthesis in a dose-dependent manner, whereas no major changes were observed in protein synthesis of the housekeeping genes hsp90 and tubulin.
Finally, the effects of BAY 43-9006 on Mcl-1 protein synthesis were examined under conditions in which proteasome function was inhibited by MG132. These studies yielded several findings. First, BAY 43-9006 markedly decreased the extent of [ 35 S]methionine incorporation into Mcl-1 in the presence of MG132, arguing against the possibility that proteasomal degradation was responsible for diminished methionine uptake (Fig. 8D) (49, 50) . To investigate further mechanisms by which BAY 43-9006 might inhibit Mcl-1 translation, we examined the status of the initiation complex eIF4F, which consists of eIF4E (a mRNA cap-binding protein), eIF4G (a scaffolding protein), and eIF4A (an ATP-dependent RNA helicase). As shown in Fig. 9A , treatment with BAY 43-9006 resulted in a rapid and striking suppression of eIF4E protein phosphorylation, which persisted over the entire treatment interval. On the other hand, levels of total eIF4E protein remained unchanged following BAY 43-9006 treatment. In contrast to eIF4E, levels of both total and phosphorylated eIF4G were increased following treatment with BAY 43-9006, whereas phosphorylation of the eIF4E-binding protein 1 exhibited no major changes over the initial 4 h of treatment, although phosphorylation declined slightly at later intervals.
To test whether BAY 43-9006 has an effect on the eIF4F assembly and cap structure recognition process, eIF4E and associated factors were isolated with m 7 -GTP-Sepharose and subjected to Western blot analysis. As shown in Fig. 9B , BAY 43-9006 did not affect the ability of eIF4E to recognize m 7 -GTP, which mimics the mRNA cap structure, nor did it modify eIF4E and eIF4G binding. This observation is in agreement with previous studies demonstrating that eIF4E dephosphorylation does not diminish its ability to recognize the mRNA cap structure (51) .
It has been shown recently that phosphorylation of eIF4E enhances the expression of cyclin D1 by potentiating cyclin D1 mRNA nucleocytoplasmic transport (52) . Consequently, attempts were made to determine whether dephosphorylation of eIF4E might be involved in Mcl-1 down-regulation. As shown in Fig. 9C , transfection of K562 cells with constitutively active MNK1 (CA-MNK1), an eIF4E kinase, alone or together with eIF4E resulted in a pronounced increase in phosphorylated eIF4E protein levels. Interestingly, treatment with BAY 43-9006 potently inhibited eIF4E phosphorylation in cells in which phosphorylation of eIF4E was enforced by ectopic expression of CA-MNK1 and/or eIF4E. Notably, induction of constitutively active MEK1 failed to prevent BAY 43-9006 mediated eIF4E dephosphorylation (Fig. 9D) . Finally, BAY 43-9006 continued to suppress eIF4E phosphorylation in the presence of the phosphatase inhibitor okadaic acid (data not shown), arguing against the possibility that BAY 43-9006 accelerates eIF4E dephosphorylation by activating PP2A, a protein phosphatase that has been implicated in eIF4E dephosphorylation (53) . Together these observations suggest that BAY 43-9006 potently suppresses eIF4E phosphorylation through a MEK/ERK-independent mechanism, and raise the possibility that this phenomenon may be involved in inhibition of Mcl-1 translation. Whether BAY 43-9006 directly inhibits the activity of MNK1 or other unknown eIF4E kinases remains to be determined. 35 S]methionine for an additional 2 h. The cells were subsequently lysed, and protein lysates were subjected to immunoprecipitation using Mcl-1 antibodies followed by electrophoresis and autoradiography. Alternatively the immunoprecipitates were subjected to Western blot analysis using Mcl-1 antibodies. The blots shown are representative of three separate experiments. FIGURE 9. Exposure to BAY 43-9006 is associated with the potent dephosphorylation of the eIF4E translation initiation factor. A, U937 cells were exposed to 10 M BAY 43-9006 for the indicated periods after which protein lysates were prepared and subjected to Western blot analysis using the indicated antibodies (CF ϭ cleavage fragment). B, U937 cells were treated with 10 M BAY 43-9006 for 2 or 4 h after which eIF4E was pulled down using m 7 -GTP-Sepharose column as described under "Materials and Methods," and subjected to Western blot analysis using eIF4E and eIF4G antibodies. C, K562 cells were transiently transfected with pSR␣ empty vector, HA-eIF4E, or myc-CA-MNK1 plasmids, cultured for 20 h, and then treated with 6 M BAY 43-9006 for 4 h, after which protein lysates were prepared and subjected to Western blot analysis using designated antibodies. D, Jurkat cells inducibly expressing constitutively active MEK1 were left untreated or treated for 24 h with 2 g/ml doxycycline and then exposed to 10 M BAY 43-9006 for an additional 4 h, after which cells were lysed and a Western blot was performed to monitor phospho-eIF4E levels. The blots were subsequently reprobed with antibody directed against ␣-tubulin to control for equal loading and transfer of proteins. The blots shown are representative of three separate experiments.
Enforced Expression of Mcl-1 Substantially Blocks BAY 43-9006-mediated Mitochondrial Injury, Caspase Activation, and Apoptosis in Human Leukemia
increases in Mcl-1 protein levels compared with empty vector control cells (pCEP4, Fig. 10A ), were employed. Significantly, apoptosis monitored after 24-and 48-h exposure to 10 M BAY 43-9006 was substantially attenuated in both Mcl-14 and Mcl-16 cells compared with their empty vector counterpart (pCEP4) (p Ͻ 0.001 in each case; Fig. 10B ). Western blot analysis revealed that, although BAY 43-9006 reduced protein levels of Mcl-1 in both clones, as one would expect of an inhibitor of translation, Mcl-1 expression in treated mutant cells was comparable to that of untreated empty vector cells (Fig. 10C) .
To , and 24 h failed to promote caspase-9 cleavage and resulted only in minimal cleavage of caspase-3 and -7, and PARP degradation in these cells (Fig. 10G) . In contrast, pronounced cytochrome c release, and marked cleavage of caspase-7, -9, and -3 as well as PARP degradation were observed in empty vector controls (pCEP4). Together, these findings support the notion that elimination of Mcl-1 is required for BAY 43-9006 to promote mitochondrial injury, caspase activation, and apoptosis in human leukemia cells.
DISCUSSION
The results of the present study indicate that treatment with BAY 43-9006, an agent currently undergoing phase II/III clinical evaluation (18 -20) , results in a striking increase in mitochondrial injury, caspase activation, and apoptosis in human leukemia cells, events that are associated with inactivation of the MEK/ERK pathway. Furthermore, this agent was effective in inducing cell death in multiple leukemia cell lines, including those expressing the Bcr-abl oncogene, as well as in primary AML blasts. Notably, the present studies demonstrate that treatment of such cells with BAY 43-9006 results in a marked decrease in Mcl-1 protein levels through inhibition of translation and that this event plays an important functional role in BAY 43-9006-mediated lethality.
In view of extensive evidence that Mcl-1 plays a critical role in the survival of malignant hematopoietic cells, including leukemia and myeloma cells (24, 25) , the development of compounds that diminish Mcl-1 protein levels has been the focus of intense interest. Indeed, a number of studies have documented down-regulation of Mcl-1 protein during apoptosis induced by a variety of agents, including, UV, ␥-irradiation, etoposide, staurosporine, STI-571, and growth factor withdrawal (28, 31, 54, 55) among others. Interestingly, several cyclin-dependent kinase inhibitors, such as flavopiridol and roscovitine, also down-regulate Mcl-1 expression in leukemia and myeloma cells (56, 57) . This phenomenon may reflect the capacity of these agents to inhibit RNA polymerase II, and thus to act as transcriptional repressors (56, 58) . The present results reveal that BAY 43-9006 induces a rapid and sharp decline in Mcl-1 protein levels. A critical question then arises regarding the mechanism by which Mcl-1 down-regulation occurs. In this regard, Mcl-1 protein levels are known to be regulated through several different mechanisms, including those operating at the transcriptional, translational, and post-translational levels.
It has been shown that Mcl-1, like other Bcl-2 family members, can be the target of degradation by caspase-3 (29, 59 (46) . It has also been reported that activation of Mcl-1 gene transcription in response to interleukin-3 is mediated through CREB and ETS transcription factors (44, 45) . In the present study, using real-time PCR, we found that BAY 43-9006 failed to decrease substantially Mcl-1 mRNA levels. Furthermore, results of actinomycin D studies, in which BAY 43-9006 decreased Mcl-1 expression despite inhibition of transcription, as well as luciferase gene reporter assays, were most compatible with transcription-independent effects. Collectively, these findings argue against the possibility that BAY 43-9006 down-regulates Mcl-1 protein through promoter activity repression or mRNA destabilization.
Another major mechanism by which Mcl-1 protein level can be regulated is degradation by the proteasome system (28, 47, 48 Thus, in cells co-exposed to BAY 43-9006 and MG132, the effects of concomitant inhibition of protein synthesis and proteasomal degradation effectively counteracted each other, resulting in no change in total protein levels. Collectively, these findings argue strongly against the possibility that BAY 43-9006 acts at the post-translational level to diminish Mcl-1 protein stability. This interpretation is also consistent with the failure of BAY 43-9006 to significantly enhance Mcl-1 ubiquitination, a phenomenon that precedes degradation by the proteasome system (54) .
Having ruled out a significant role for altered Mcl-1 transcription, the stability of mRNA, or the stability of the protein, the major remaining possibility is that translation of Mcl-1 must decrease in cells exposed to BAY 43-9006. Indeed, as noted above, assessment of protein synthesis revealed a marked inhibition of Mcl-1 translation following exposure to BAY 43-9006. Diminished Mcl-1 translation has been implicated in Mcl-1 down-regulation in several systems, including HeLa cells exposed to UV (28) and Jurkat cells exposed to salicylate (54) , although the precise mechanism underlying these actions remains to be elucidated. In general, translation is primarily regulated at the initiation phase, a multistep process orchestrated by a several initiation factors. Translation of most of mRNAs is dependent upon the cap structure m 7 -GTP which is found at the 5Ј terminus of all cellular eukaryotic mRNAs. The initiation complex eIF4F, a heterotrimeric protein composed of eIF4E, eIF4G, and eIF4A, plays a critical role in the translation of these mRNAs. eIF4E, also known as the cap-binding protein, represents the rate-limiting member of the eIF4F complex and binds directly to the 5Ј-terminal m 7 -GTP cap, resulting in recruitment of ribosomes to the 5Ј-end of mRNA transcripts. In addition, emerging evidence indicates that eIF4E is an important target of translation regulation through several functional post-translational modifications, including phosphorylation and ubiquitination (61, 62) . Increased expression of eIF4E has been observed in various human cancer cells (63) and is associated with increased translation of several mRNAs, including Bcl-x L , ornithine decarboxylase, and c-myc, among others (64) . Although the role of eIF4E phosphorylation in translation initiation is incompletely understood, it has recently been shown to enhance expression of cyclin D1 by increasing mRNA nucleocytoplasmic transport (65) , suggesting that, for at least some mRNAs, eIF4E phosphorylation promotes translation. In this context, it is noteworthy that BAY 43-9006 rapidly and potently suppressed phosphorylation of eIF4E, although no apparent effect on eIF4F assembly or m 7 -GTP affinity could be detected. A clearer characterization of the functional role of eIF4E dephosphorylation in disruption of Mcl-1 translation by BAY 43-9006, as well as the possible participation of additional translation initiation factors (e.g. eIF2␣), await further study.
The control of translation has also been linked to various signal transduction cascades. For example, eIF4E is known to be phosphorylated by MAP kinase-interacting kinases MNK1 and MNK2, factors that lie downstream of MEK/ERK1-2 and p38 MAP kinases (37, 66) . Interestingly, enforced expression of constitutively active MEK1 or MNK1 failed to prevent BAY 43-9006-mediated suppression of eIF4E phosphorylation. Significantly, enforced activation of these kinases also failed to block BAY 43-9006-induced Mcl-1 down-regulation. Although the mechanism by which BAY 43-9006 suppresses eIF4E phosphorylation and the functional role of this phenomenon in Mcl-1 down-regulation remain to be determined, these data suggest that in addition to its well characterized role in Raf/MEK/ERK inhibition, BAY 43-9006 may also modify translation initiation factors independently of its effects on this signaling cascade to disrupt Mcl-1 translation. It should be noted that such translation initiation factors are not selective for Mcl-1 translation. However, because the half-lives of Mcl-1 mRNA and protein are relatively short (e.g. 2.5 h and 30 min, respectively) (67, 68) , interference with Mcl-1 synthesis is likely to have a major effect on protein levels. Finally, other signaling cascades (e.g. p90RSK, mTOR, and p70S6K), including those related to stress responses (e.g. p38), have been linked to the regulation of protein synthesis (69 -71) . However, the data presented here argue that these factors are unlikely to be primarily involved in BAY 43-9006 mediated Mcl-1 down-regulation. Nevertheless, the possibility that other stress-related pathways (e.g. PKR-like endoplasmic reticulum kinase) may be implicated in the inhibition of Mcl-1 translation by BAY 43-9006 cannot be completely excluded, and such pathways are currently the subject of ongoing investigation.
It is significant that enforced expression of Mcl-1 markedly diminished BAY 43-9006-mediated lethality in both U937 and K562 cells, arguing that down-regulation of this protein played a critical functional role in BAY 43-9006 lethality. In accord with this notion, Mcl-1 overexpression largely inhibited caspase activation and release of cytochrome c into the cytosol. These findings are consistent with the studies described by Nijhawan et al. (28) , who demonstrated that Mcl-1 operates upstream of Bax and Bcl-x L translocation to the mitochondria, cytochrome c release, and caspase activation in UV-treated HeLa cells. Interestingly, in this study, a decline in Mcl-1 protein was not sufficient by itself to induce apoptosis, suggesting that one or more additional perturbations are involved in lethality. Similar results have been observed in Jurkat cells (54) . However, other studies have demonstrated that down-regulation of Mcl-1 through the use of antisense oligonucleotides or small interference RNA is sufficient to induce apoptosis in U937 (24) and myeloma cells (30, 72, 60) . In the present study, it should be noted that Mcl-1 overexpression did not completely block BAY 43-9006-induced lethality. Consequently, the possibility that other BAY 43-9006-mediated actions contribute to induction of apoptosis cannot be completely excluded. In summary, the present findings indicate that the Raf inhibitor BAY 43-9006 effectively induces cell death in Bcr/Abl ϩ or Bcr/Abl Ϫ human leukemia cells, as well as in primary AML blasts.
Furthermore, these events occur in association with the rapid downregulation of Mcl-1 primarily through inhibition of translation, rather than through a transcriptional or post-translational mechanism. Moreover, this phenomenon is associated with the rapid and potent dephosphorylation of the eIF4E translation initiation factor, which has been implicated in protein synthesis regulation. Significantly, enforced expression of Mcl-1 was able to block cytochrome c release, caspase activation, and apoptosis in U937 and K562 cells exposed to BAY 43-9006, arguing that down-regulation of this anti-apoptotic protein plays a critical functional role in the lethality of this agent. Although previous studies have focused on the inhibitory effects of BAY 43-9006 on the Raf/MEK/ERK pathway as the possible basis of action of this compound (2), the finding that BAY 43-9006 promotes apoptosis through the MEK/ERK-independent inhibition of Mcl-1 translation suggests an additional dimension to its mode of cell killing, at least in human leukemia cells. Further efforts to elucidate the mechanism(s) by which BAY 43-9006 inhibits translation of anti-apoptotic protein Mcl-1, and the possible role of disruption of translation initiation factors in this process, could provide a more rational basis for developing this compound either alone or in combination with established chemotherapeutic agents in leukemia and potentially other hematologic malignancies.
